NCT01288417View on ClinicalTrials.gov

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
HIV InfectionsHCV Infections
Interventions
DRUG

boceprevir

10 days of boceprevir 800mg TID

DRUG

raltegravir

raltegravir 400mg single dose

Trial Locations (1)

Unknown

CRCN, Nijmegen

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT01288417 - Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir | Biotech Hunter | Biotech Hunter